15-lipoxygenase-2 gene regulation by its product 15-(S)-hydroxyeicosatetraenoic acid through a negative feedback mechanism that involves peroxisome proliferator-activated receptor γ

被引:23
作者
Subbarayan, V.
Krieg, P.
Hsi, L. C.
Kim, J.
Yang, P.
Sabichi, A. L.
Llansa, N.
Mendoza, G.
Logothetis, C. J.
Newman, R. A.
Lippman, S. M.
Menter, D. G.
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Unit 1360, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
[4] German Canc Res Ctr, Dept Eicosanoids & Tumor Dev, D-6900 Heidelberg, Germany
关键词
15-lipoxygenase-2; prostate cancer; gene expression; peroxisome proliferator-activated receptor gamma;
D O I
10.1038/sj.onc.1209617
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
An inverse relationship exists between the expression of 15-lipoxygenase-2 (15-LOX-2) and peroxisome proliferator-activated receptor c (PPARc) in normal prostate epithelial cells (PrECs) compared with their expression in prostate carcinoma cells (PC-3). The reason for this difference, however, is unknown. We hypothesized that this inverse expression partly involves the 15-LOX-2 promoter and 15-S-hydroxyeicosatetraenoic acid (15-(S)HETE), a product of 15- LOX-2 that binds to PPARc. We identified an active steroid nuclear receptor half-site present in the 15-LOX-2 promoter fragment F-5 (-618/+177) that can interact with PPARc. After forced expression of wild-type PPARc, 15-(S)-HETE (1 mu M) decreased F-5 reporter activity in PrECs whereas forced expression of 15-LOX-2 resulted in 15-(S)-HETE production which enhanced F-5 activity in PC-3. In contrast, the expression of dominant-negative PPARc reversed the transcriptional activation of F-5 by enhancing it 202-fold in PrEC or suppressing it in PC-3; the effect in PC-3 was positively increased 150-fold in the presence of 15-(S)-HETE (1 mu M). Peroxisome proliferator-activated receptor c interacted with 15-LOX-2 promoter sequences in pulldown experiments using biotinylated 15-LOX-2 (-560/-596 bp) oligonucleotides. In gelshift analyses PPARc and orphan receptor ROR alpha were shown to interact with the F-5 fragment in PC-3 cells. These data suggest that crosstalk mechanisms exist between the 15-LOX-2 gene and PPARc to counterbalance expression and help explain the inverse relationship of these genes in normal versus cancer cells.
引用
收藏
页码:6015 / 6025
页数:11
相关论文
共 40 条
[21]   Activation of the orphan nuclear receptor RORα counteracts the proliferative effect of fatty acids on prostate cancer cells:: Crucial role of 5-lipoxygenase [J].
Moretti, RM ;
Marelli, MM ;
Sala, A ;
Motta, M ;
Limonta, P .
INTERNATIONAL JOURNAL OF CANCER, 2004, 112 (01) :87-93
[22]  
Moretti RM, 2002, ONCOL REP, V9, P1139
[23]  
Moretti RM, 2001, PROSTATE, V46, P327, DOI 10.1002/1097-0045(20010301)46:4<327::AID-PROS1040>3.0.CO
[24]  
2-6
[25]   Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ [J].
Nagy, L ;
Tontonoz, P ;
Alvarez, JGA ;
Chen, HW ;
Evans, RM .
CELL, 1998, 93 (02) :229-240
[26]   Alleviating the suppression of glycogen synthase kinase-3β by Akt leads to the phosphorylation of cAMP-response element-binding protein and its transactivation in intact cell nuclei [J].
Salas, TR ;
Reddy, SA ;
Clifford, JL ;
Davis, RJ ;
Kikuchi, A ;
Lippman, SM ;
Menter, DG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (42) :41338-41346
[27]   RAPID DETECTION OF OCTAMER BINDING-PROTEINS WITH MINI-EXTRACTS, PREPARED FROM A SMALL NUMBER OF CELLS [J].
SCHREIBER, E ;
MATTHIAS, P ;
MULLER, MM ;
SCHAFFNER, W .
NUCLEIC ACIDS RESEARCH, 1989, 17 (15) :6419-6419
[28]   IL-4 induces apoptosis in A549 lung adenocarcinoma cells:: Evidence for the pivotal role of 15-hydroxyeicosatetraenoic acid binding to activated peroxisome proliferator-activated receptor γ transcription factor [J].
Shankaranarayanan, P ;
Nigam, S .
JOURNAL OF IMMUNOLOGY, 2003, 170 (02) :887-894
[29]   15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma [J].
Shappell, SB ;
Boeglin, WE ;
Olson, SJ ;
Kasper, S ;
Brash, AR .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (01) :235-245
[30]  
Shappell SB, 2001, CANCER RES, V61, P497